Business
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA
10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against
About this update from Geovax Labs, Inc.
[{"type":"text","content":"\n10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19\n \nStudy is Funded by BARDA through Project NextGen, executed through its Clinical Studies Network\n \nATLANTA, GA - (NewMediaWire) - June 27, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it will partner with Allucent, a global clinical research organization (CRO), to conduct a Phase 2b clinical trial of GEO-CM04S1, GeoVax's dual-antigen next-generation COVID-19 vaccine.\n \nGeoVax previously announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) to advance development of GEO-CM04S1, GeoVax's dual-antigen next-generation COVID-19 vaccine, in a Phase 2b clinical trial. The RRPV is a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).\n \nUnder the agreement, GeoVax will sponsor a 10,000-participant, randomized, Phase 2b double-blinded study to evaluate the relative efficacy of GEO-CM04S1 compared to an approved/authorized COVID-19 vaccine to prevent symptomatic, PCR-confirmed SARS-CoV-2 infection. As part of BARDA's Clinical Studies Network, Allucent will initiate and implement the BARDA-funded study. The combined value of the awards to GeoVax and Allucent toward the clinical evaluation of GEO-CM04S1 is approximately $367 million.\n \nDavid Dodd, Chairman & CEO of GeoVax, stated, \"The work supported by BARDA's Project NextGen will significantly advance the collective efforts to combat COVID-19 and its variants, and we are proud that GEO-CM04S1 was selected to be part of those critically important initiatives. We are delighted to be collaborating with Allucent on this important study.\"\n \nMark A. Goldberg, M.D., Chairman and CEO of Allucent, commented, \"We are honored to have been previously chosen by BARDA to be part of its Clinical Studies Network for this critical initiative and pleased to be offered the opportunity to execute the Phase 2b trial of GEO-CM04S1 in collaboration with GeoVax. We are excited to leverage our clinical devel...